Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan;11(1):29–42. doi: 10.21037/tcr-21-1951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Translational Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Kaplan-Meier survival analysis for different molecular subtypes of breast patients according to CD47-MCT1 expression. (A,D) 10-OS and 10-DFS in luminal (A+B) breast cancer patients. (B,E) 10-OS and 10-DFS in HER2 overexpression breast cancer patients. (C,F) 10-OS and 10-DFS in basal like breast cancer patients. P values were obtained using the log-rank test. OS, overall survival; DFS, disease-free survival; 10-OS, 10-year overall survival rate; 10-DFS, 10-year progression-free survival rate; HER2, human epidermal growth factor receptor 2; CD47, cluster of differentiation 47; MCT1, monocarboxylate transporter 1.